Sign in
CompletedNo phase

Eosinophilic Esophagitis Steroid Safety Study

Key facts

Who runs it
Rabin Medical Center
Where
Greece, Israel, and Italy4 sites in 3 countriesChoose a country to see its sites
Trial code
Status
Completed
People taking part
55 people enrolled
Started
7 Oct 2019
Ended
31 Dec 2024
Type of study
Observational
Record updated
7 May 2025

Who can take part

Age
Up to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age <18 years at the time of enrollment
  • Males and Females are included
  • Patients diagnosed with EoE as defined by age appropriate signs of esophageal dysfunction (in older children and adolescents - dysphagia, impacted food bolus, foreign body impaction, vomiting, and GERD not responsive to high dose proton pump inhibitors. In infants and young children - failure to thrive, poor feeding, vomiting, food bolus impaction)
  • Histopathological finding of ≥15 eosinophils/high power field (X400) on at least one esophageal biopsy
  • After discussing the available treatment options with the gastroenterologist, the patient has chosen oral topical steroid treatment (either as a first treatment or after failure of other dietary or medical treatment)

Who cannot take part

  • Use of oral systemic steroids in the 6 months prior to inclusion in the study. Use of systemic steroids once in the study will not lead to study termination, but such use will need to be reported in the medication changes and use page of the following visit
  • Known allergy to topical steroids ingredients
  • Known alternative causes of esophageal eosinophilia
  • Legal guardian unable or unwilling to sign informed consent
  • Patient will not be available for follow-up for at least the 3 month assessment and ACTH test
  • Known pregnancy

Where is this trial?

It has sites in 3 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This observational study will follow pediatric patients with eosinophilic esophagitis who are scheduled to begin topical steroid treatment, from the initiation of treatment longitudinally to determine the safety profile of the drug.

The group in the trial

  • Topical Steroid Treatment

    Pediatric patients with eosinophilic esophagitis scheduled to begin topical steroid treatment for the treatment of their condition. The type of topical steroid is not limited and is at the discretion of the treating physician as are dosing and concomitant treatments.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Adrenal Suppression in Pediatric Eosinophilic Esophagitis Treated With Topical Steroids - A Multicenter, Prospective, Observational Safety Study
Record updated
7 May 2025